Long term results from OPTiM phase III trial with T-VEC, the first armed OV approved by FDA and EMA in melanoma, have revealed the advantage of HSV-1 expressing GM-CSF vs GM-CSF administered in its proteinaceous form. The gene discussed is CSF2; the disease is melanoma.